FDA Archives - Page 164 of 220

5 minute read

FDA
News

AnaptysBio And GSK-Partnered Immuno-Oncology Agents JEMPERLI (dostarlimab-gxly) And Cobolimab Show Progress In Two Separate Non-small Cell Lung Cancer Trials

October 5, 9:02 AM

AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials Positive headline results from PERLA, a head-to

ANAB

4 minute read

Acer Therapeutics Announces Expansion Of ACER-801 Development Indications To Include Post-Traumatic Stress Disorder

By Benzinga Newsdesk

October 5, 8:32 AM

Licensed exclusive worldwide rights from Emory University to patents and patent applications for certain methods of treating or preventing post-traumatic stress disorder (PTSD) with osanetant Osanetant targets a

ACER

1 minute read

Leap Therapeutics To Present Updated Data From The DisTinGuish Study Of DKN-01 Plus Tislelizumab And Preclinical Data In Colorectal Cancer Models At The Society of Immunotherapy for Cancer Annual Meeting

By Benzinga Newsdesk

October 5, 8:19 AM

CAMBRIDGE, Mass., Oct. 5, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be

LPTX

1 minute read

AbCellera Announces Presentation Of Data From CD3 T-Cell Engager Platform At Society for Immunotherapy of Cancer November 11 2022

By Benzinga Newsdesk

October 5, 8:11 AM

AbCellera (NASDAQ:ABCL) today announced a presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, to be held virtually and at the Boston Convention & Exhibition Center from November 8

ABCL

1 minute read

E-Cigarette Maker Juul Mulls Potential Bankruptcy

By Vandana Singh

October 5, 7:51 AM

Juul Labs Inc, backed by Altria Group Inc (NYSE: MO), has been exploring various options—including bankruptcy—after the FDA issued its marketing denial order.

1 minute read

On Oct 3, 2022, Avidity Biosciences Announced Its Planned Fortitude Trial Of AOC 1020 In Adult Participants With Facioscapulohumeral Muscular Dystrophy

By Benzinga Newsdesk

October 4, 4:13 PM

- Reuters

RNA

1 minute read

FDA Puts Partial Hold On Aeglea’s Rare Disorder Trial In Pediatric Patients

By Vandana Singh

October 4, 11:05 AM

Aeglea BioTherapeutics Inc (NASDAQ:AGLE) received an FDA letter responding to a recently submitted protocol amendment for the Phase 1/2 trial of…

AGLE

1 minute read

Inhibrx’s Experimental Drug For Inherited Disease Capable For Accelerated FDA Approval, Shares Surge

By Vandana Singh

October 4, 9:28 AM

Based on discussions with the FDA, Inhibrx Inc (NASDAQ:INBX) has the potential to pursue accelerated approval for INBRX-101 for emphysema due to…

INBX

2 minute read

Zymeworks Reminds Shareholders To Vote FOR Its Redomicile

By Benzinga Newsdesk

October 4, 8:43 AM

The Redomicile is anticipated to provide greater opportunities to enhance long-term value for securityholders, simplify commercialization efforts and monetization opportunities for our product candidates, and provide

ZYME

1 minute read

FDA
News

Biotricity Says Surpasses 2B Recorded And Analyzed Heartbeats For Atrial Fibrillation

By Benzinga Newsdesk

October 4, 8:33 AM

Data set of 2 billion heartbeats and growing allows Biotricity to scale faster and operate more efficiently with better automation, yielding growth and better margins in the future

BTCY